Cargando…
Personalized Clostridioides difficile engraftment risk prediction and probiotic therapy assessment in the human gut
Clostridioides difficile colonizes up to 30–40% of community-dwelling adults without causing disease(1,2). C. difficile infections (CDIs) are the leading cause of antibiotic-associated diarrhea in the U.S.(3,4) and typically develop in individuals following disruption of the gut microbiota due to an...
Autores principales: | Carr, Alex, Baliga, Nitin S., Diener, Christian, Gibbons, Sean M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168307/ https://www.ncbi.nlm.nih.gov/pubmed/37162960 http://dx.doi.org/10.1101/2023.04.28.538771 |
Ejemplares similares
-
Gut metabolites predict Clostridioides difficile recurrence
por: Dawkins, Jennifer J., et al.
Publicado: (2022) -
Consortium of Probiotics Attenuates Colonization of Clostridioides difficile
por: Li, Xianping, et al.
Publicado: (2019) -
Successful Bacterial Engraftment Identified by Next-Generation Sequencing Predicts Success of Fecal Microbiota Transplant for Clostridioides difficile
por: Hazan, Sabine, et al.
Publicado: (2021) -
Clostridioides difficile Is Not Difficult to Predict in Hospital Settings
por: Alexander, Kinta, et al.
Publicado: (2021) -
Gut microbiota and microbiota-based therapies for Clostridioides difficile infection
por: Chopra, Teena, et al.
Publicado: (2023)